MENU

CYCC Stock Cyclacel Pharmaceuticals (CYCC, $12.33) Stochastic Oscillator left the oversold zone on July 15, 2025

A.I.dvisor
at Tickeron.com
Loading...
CYCC - Cyclacel Pharmaceuticals Inc
Stochastic signal
Bullish Trend
Odds of UP Trend
Tickeron
Stochastic signal
Price: $12.33
Daily change: +$9.02 (+272.51%)
Daily volume: 62.3M
Capitalization: $19.5M
Industry: Biotechnology
This is a signal that CYCC's price trend could be reversing, and it may be an opportunity to buy the stock or explore call options. A.I.dvisor identified 68 similar cases where CYCC's stochastic oscillator exited the oversold zone, and of them led to successful outcomes. Odds of Success:

CYCC sees its Stochastic Oscillator ascends from oversold territory

On July 15, 2025, the Stochastic Oscillator for CYCC moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 67 instances where the indicator left the oversold zone. In of the 67 cases the stock moved higher in the following days. This puts the odds of a move higher at over .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on July 15, 2025. You may want to consider a long position or call options on CYCC as a result. In of 76 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

CYCC moved above its 50-day moving average on July 23, 2025 date and that indicates a change from a downward trend to an upward trend.

Following a +5 3-day Advance, the price is estimated to grow further. Considering data from situations where CYCC advanced for three days, in of 234 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The RSI Indicator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CYCC declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

CYCC broke above its upper Bollinger Band on July 18, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for CYCC entered a downward trend on July 14, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. CYCC’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (8.873) is normal, around the industry mean (18.664). P/E Ratio (0.397) is within average values for comparable stocks, (59.851). CYCC's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.578). Dividend Yield (0.000) settles around the average of (0.044) among similar stocks. P/S Ratio (1111.111) is also within normal values, averaging (279.346).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CYCC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
CYCC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a developer of mechanism-targeted drugs to treat human cancers

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
200 Connell Drive
Phone
+1 908 517-7330
Employees
12
Web
https://cyclacel.com